Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation

被引：0
|
作者：
Andronikou, Christina
Burdova, Kamila
Dibitetto, Diego
Lieftink, Cor
Beijersbergen, Roderick L.
Hanzlikova, Hana
Jonkers, Jos
Rottenberg, Sven
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-LB_A25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB_A25
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors
    Rasco, Drew W.
    McKean, Meredith
    Haydon, Andrew Mark
    Weickhardt, Andrew James
    Frentzas, Sophia
    Ahern, Elizabeth Stephanie
    Powderly, John D., II
    Wyant, Timothy
    Tang, Jenny
    Richards, Lori
    Knickerbocker, Aron
    Amit, Inbar
    Ofran, Yanay
    Vasselli, James Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation
    Coutre, Steven E.
    Leonard, John P.
    Barrientos, Jacqueline C.
    De Vos, Sven
    Flinn, Ian
    Furman, Richard R.
    Brown, Jennifer R.
    Wagner-Johnston, Nina
    Benson, Don M., Jr.
    Schreeder, Marshall T.
    Sharman, Jeff P.
    Boyd, Thomas
    Spurgeon, Stephen
    Zelenetz, Andrew D.
    Lamanna, Nicole
    Kipps, Thomas J.
    Kahl, Brad S.
    Bello, Celeste M.
    Burger, Jan A.
    Rai, Kanti R.
    Dansey, Roger
    Kim, Yeonhee
    Holes, Leanne M.
    Lazarov, Mirella
    Dubowy, Ronald L.
    O'Brien, Susan M.
    BLOOD, 2013, 122 (21)
  • [33] Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)
    Siegel, David S.
    Berdeja, Jesus G.
    Infante, Jeffrey R.
    Kaufman, Jonathan L.
    Wang, Michael
    Martin, Thomas G.
    Niesvizky, Ruben
    Reu, Frederic J.
    Jagannath, Sundar
    Rajangam, Kanya
    Huang, Mei
    Vij, Ravi
    BLOOD, 2014, 124 (21)
  • [34] Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors
    Papadopoulos, K. P.
    Gutierrez, M.
    Duska, L. R.
    Gandhi, L.
    Bommi-Reddy, A.
    Adams, E.
    Jauch-Lembach, J.
    Rasco, D. W.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S67 - S67
  • [35] Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial
    Nemunaitis, J
    Ganly, I
    Khuri, F
    Arseneau, J
    Kuhn, J
    McCarty, T
    Landers, S
    Maples, P
    Romel, L
    Randlev, B
    Reid, T
    Kaye, S
    Kirn, D
    CANCER RESEARCH, 2000, 60 (22) : 6359 - 6366
  • [36] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
    Fakih, M.
    Durm, G.
    Govindan, R.
    Falchook, G.
    Soman, N.
    Henary, H.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
  • [37] Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-a*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation
    Becerra, Carlos Roberto
    Awad, Mark M.
    Hecht, J. Randolph
    Paulson, Andrew Scott
    Lee, Jennifer
    Palluconi, Gabi
    Dalton, Jaquelin
    Patel, Anuradha
    Yan, Ying
    Perez, Arianne
    Xie, Sunny
    Cohen, Sarah
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
    Hong, M. H.
    Spira, A. I.
    Lee, K. H.
    Cho, E. K.
    Han, J-Y.
    Shim, B. Y.
    Lee, J-S.
    Kao, S. C-H.
    Kim, S-W.
    Khattak, A.
    Patel, M.
    Xu, R.
    Wang, J.
    Ariazi, E.
    Daemen, A.
    Maneval, E. Chow
    Multani, P. S.
    Patel, R.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [39] First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
    Yap, T. A.
    Dowlati, A.
    Dagogo-Jack, I.
    Vibert, J.
    Spira, A. I.
    Garcia, V. Moreno
    Punekar, S. R.
    Calvo, E.
    Sonpavde, G. P.
    Awad, M.
    Riess, J. W.
    Hernandez-Guerrero, T.
    Herzberg, B.
    Italiano, A.
    Swalduz, A.
    LoRusso, P.
    Smit, E. F.
    Garon, E. B.
    Novotny, W.
    Guo, R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S1 - S2
  • [40] Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors
    Sen, Shiraj
    Call, Justin A.
    Papadopoulos, Kyriakos P.
    Smith, F. Donelson
    McDermott, Janine
    van der Horst, Edward
    Weitzman, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345